68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .
Pharmacist-Led Group Medical Appointment Model in Type 2 Diabetes
Purpose The purpose of this study was to assess whether the VA-MEDIC ( Veterans Affairs Multi-disciplinary Education and Diabetes Intervention for Cardiac risk reduction ) , a pharmacist-led group medical visit program , could improve achievement of target goals in hypertension , hyperglycemia , hyperlipidemia , and tobacco use in patients with type 2 diabetes compared to usual care . Methods This was a r and omized controlled trial of VA-MEDIC intervention in addition to usual care versus usual care alone in diabetic patients to reduce cardiac risk factors . VA-MEDIC consisted of a 40- to 60-minute educational component by nurse , nutritionist , physical therapist , or pharmacist followed by pharmacist-led behavioral and pharmacological interventions over 4 weekly sessions . Measures The attainment of target goals in hemoglobin A1C ( A1C ) , blood pressure , fasting lipids , and tobacco use recommended by the American Diabetes Association . Results Of 118 participants , 109 completed the study . VA-MEDIC ( n = 58 ) participants were younger and had greater tobacco use at baseline than usual care but were similar in other cardiovascular risk factors . After 4 months , a greater proportion of VA-MEDIC participants versus controls achieved an A1C of less than 7 % and a systolic blood pressure less than 130 mm Hg . No significant change was found in lipid control or tobacco use between the 2 study arms . Conclusion Pharmacist-led group medical visits are feasible and efficacious for improving cardiac risk factors
68 % of the outcomes reported showed that clinical pharmacy services were associated with better improvement in patients ' outcomes compared with the control group .
The involvement of a pharmacist demonstrated an ability to improve CVD outcomes through providing educational intervention , medicine management intervention , or a combination of both .
These interventions result ed in improved CVD risk factors , improved patient outcomes , and reduced number of drug-related problems with a direct effect on CVD control .
These improvements may lead to an improvement in patient quality of life , better use of health care re sources , and a reduced rate of mortality
BACKGROUND Cardiovascular disease ( CVD ) is considered to be the main cause of death and one of the most common diseases affecting health care systems worldwide .
Many methods have been used to improve CVD outcomes , one of which is to involve clinical pharmacists in the direct care of patients with CVD .
OBJECTIVE To perform a systematic review assessing the effectiveness of clinical pharmacist interventions within a multidisciplinary team in the secondary prevention of CVD , using studies conducted on patients with heart failure , coronary heart disease , or those with CVD risk factors .